These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1525595)

  • 41. Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.
    Stoeckemann K; Sandow J
    J Cancer Res Clin Oncol; 1993; 119(8):457-62. PubMed ID: 8509436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiosteoporotic activity of echinacoside in ovariectomized rats.
    Li F; Yang X; Yang Y; Guo C; Zhang C; Yang Z; Li P
    Phytomedicine; 2013 Apr; 20(6):549-57. PubMed ID: 23428402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prolonged action of the LHRH agonist buserelin (HOE 766) may be due to prolonged binding to the LHRH receptor.
    Koiter TR; Denef C; Andries M; Moes H; Schuiling GA
    Life Sci; 1986 Aug; 39(5):443-52. PubMed ID: 3016440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
    Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
    J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
    Brogden RN; Buckley MM; Ward A
    Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of tocotrienol from Bixa orellana (annatto) on bone histomorphometry in a male osteoporosis model induced by buserelin.
    Mohamad NV; Soelaiman IN; Chin KY
    Biomed Pharmacother; 2018 Jul; 103():453-462. PubMed ID: 29674281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study of the direct action of luteinizing hormone-releasing hormone agonists at the testicular level in intact rats treated with an antiluteinizing hormone serum.
    Séguin C; Bélanger A; Labrie F; Hansel W
    Endocrinology; 1982 Feb; 110(2):524-30. PubMed ID: 6276140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tamoxifen but not other selective estrogen receptor modulators antagonizes estrogen actions on luteinizing hormone secretion while inducing gonadotropin-releasing hormone self-priming in the rat.
    Sánchez-Criado JE; Guelmes P; Bellido C; Gónzalez M; Hernández G; Aguilar R; Garrido-Gracia JC; Bello AR; Alonso R
    Neuroendocrinology; 2002 Oct; 76(4):203-13. PubMed ID: 12411737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogens and progestogens conserve bone in rats deficient in calcitonin and parathyroid hormone.
    Goulding A; Gold E
    Am J Physiol; 1989 Dec; 257(6 Pt 1):E903-8. PubMed ID: 2558576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids.
    Lumsden MA; West CP; Hillier H; Baird DT
    Fertil Steril; 1989 Dec; 52(6):924-9. PubMed ID: 2531684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy.
    Stroup GB; Hoffman SJ; Vasko-Moser JA; Lechowska BA; Jenkins EL; Dare LC; Gowen M
    Bone; 2001 May; 28(5):532-7. PubMed ID: 11344053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Further characterization of the direct inhibitory effect of LHRH agonists at the testicular level in the rat.
    Marchetti B; Labrie F
    J Steroid Biochem; 1984 Jan; 20(1):339-42. PubMed ID: 6323867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The less potent estrogenic effect of tamoxifen on bone in ovariectomized rats with established osteopenia.
    Li X; Takahashi M; Kushida K; Inoue T
    Calcif Tissue Int; 1998 Jun; 62(6):502-5. PubMed ID: 9576977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of rat ovarian [3H]thymidine uptake by luteinizing hormone-releasing hormone agonists: a possible mechanism for preventing damage by cytotoxic agents.
    Ataya KM; Palmer KC; Blacker CM; Moghissi KS; Mohammad SH
    Cancer Res; 1988 Dec; 48(24 Pt 1):7252-6. PubMed ID: 2973371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats.
    Ruenitz PC; Shen Y; Li M; Liang H; Whitehead RD; Pun S; Wronski TJ
    Bone; 1998 Dec; 23(6):537-42. PubMed ID: 9855462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in bone mineral content following hormone treatment for endometriosis.
    Fukushima M
    Int J Gynaecol Obstet; 1995 Sep; 50 Suppl 1():S17-22. PubMed ID: 8529770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of luteinizing hormone-releasing hormone analogue on DNA synthesis in rat prostate and uterus.
    Sakamoto S; Tajima M; Sawaki K; Suzuki S; Kudo H; Sassa S; Kuwa K; Sugiura Y; Kasahara N; Nagasawa H
    In Vivo; 1993; 7(1):13-6. PubMed ID: 8504203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of osteopenia induced with a gonadotropin-releasing hormone agonist in rats.
    Sakamoto S; Sassa S; Mitamura T; Kudo H; Suzuki S; Yoshimura S; Zhou Y; Kikuchi T; Shinoda H
    Calcif Tissue Int; 1999 Aug; 65(2):152-5. PubMed ID: 10430650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.